Acambis investors welcome the arrival of bio-'rainmaker'
The market has responded positively to news that one of UK biotech's most accomplished executives and dealmakers, Peter Fellner has joined vaccines-maker, Acambis' board.The market has responded positively to news that one of UK biotech's most accomplished executives and dealmakers, Peter Fellner has joined vaccines-maker, Acambis' board.
The Cambridge company's share price rose 3.4 per cent or 6.75p to 241.5p following the announcement that DrFellner had been appointed a non-exec director.
Dr Fellner led the development of Celltech from a small research company into the UK's leading biotechnology company. He was Celltech's CEO from 1990 to 2003 and chairman from 2003 until its acquisition by the Belgian biopharmaceutical company, UCB, in 2004.
Among other board positions, he is chairman of Cambridge-based Vernalis and Astex Therapeutics, and a non-exec director of East of England medical device manufacturer, Bespak plc.
He is also a director of one of Europe's largest technology companies, the recently floated QinetiQ Group plc.
Alan Smith, chairman of Acambis described Dr Fellner as “one of the leading figures in the UK biotechnology industry.”